Loss of function alterations in the MMR genes (MLH1, MSH2, MSH6, and PMS2) define a subgroup of patients with a high potential response to immune checkpoint blockade, which together with MSI and a higher expression of tumor neoantigens, facilitates immunological diagnosis. This evidence concerns the gene MRC1 and neoplasm.